<a href="https://laohu8.com/S/ALVO">Alvotech</a> and Advanz Pharma Secure EC Approval for Gobivaz Biosimilar to Simponi
Alvotech SA and Advanz Pharma have announced that the European Commission has granted marketing authorization for Gobivaz®, Alvotech's biosimilar to Simponi® (golimumab), across the European Economic Area $(EEA)$. Gobivaz® is the first biosimilar to Simponi® approved in Europe and will be available in multiple formulations for the treatment of several immune-mediated diseases, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and juvenile idiopathic arthritis. Under the partnership, Alvotech is responsible for development and supply, while Advanz Pharma holds exclusive commercialization rights in the EEA and UK. This approval follows a positive opinion from the EMA's Committee for Medicinal Products for Human Use.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001139966-en) on November 20, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。